Depression in neurological disorders: Parkinson disease and multiple sclerosis

Author/s
Francesca Falzon Aquilina, Mark Agius
Citation
Issue 5 Winter 2018
CEPiP.2018.1.216-221
Abstract

Depression is a not only highly prevalent in the general population but also in neurological disorders such as Parkinson disease (PD) and multiple sclerosis (MS). The manifestations, diagnosis and treatment of depression in both PD and multiple sclerosis can be complex. There is limited scientific research related to current therapies. There is a need for further research with regard to treatment options in depression for both neurological disorders.

Keywords: depression, neurological disorder, multiple sclerosis, Parkinson disease, comorbid, diagnosis, treatment, research

Cite as: Cutting Edge Psychiatry in Practice 2018, 5(1):216-221; https://doi.org/10.65031/klup1078

References

  1. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson’s disease. Biological Psychiatry. 2003 Aug 1;54(3):363-75. https://doi.org/10.1016/s0006-3223(03)00530-4
  2. Rickards H. Depression in neurological disorders: Parkinson’s disease, multiple sclerosis, and stroke. Journal of Neurology, Neurosurgery & Psychiatry. 2005 Mar 1;76(suppl 1):i48-52. https://doi.org/10.1136/jnnp.2004.060426
  3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013. https://doi.org/10.1007/s11019-013-9529-6
  4. Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW. The validity of the Hamilton and Montgomery‐Åsberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. International Journal of Geriatric Psychiatry. 2000 Jul;15(7):644-9. https://doi.org/10.1002/1099-1166(200007)15:7<644::aid-gps167>3.0.co;2-l
  5. Richard IH, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Movement Disorders: official journal of the Movement Disorder Society. 1999 Jan;14(1):155-7. https://doi.org/10.1002/1531-8257(199901)14:1<155::aid-mds1026>3.3.co;2-q
  6. Aarsland D, Larsen JP, Waage O, Langeveld JH. Maintenance electroconvulsive therapy for Parkinson's disease. Convulsive Therapy. 1997 Dec;13(4):274-7.
  7. Moellentine C, Rummans T, Ahlskog JE, Harmsen WS, Suman VJ, O'Connor MK, Black JL, Pileggi T. Effectiveness of ECT in patients with parkinsonism. The Journal of Neuropsychiatry and Clinical Neurosciences. 1998 May;10(2):187-93. https://doi.org/10.1176/jnp.10.2.187
  8. Wengel SP, Burke WJ, Pfeiffer RF, Roccaforte WH, Paige SR. Maintenance electroconvulsive therapy for intractable Parkinson's disease. The American Journal of Geriatric Psychiatry. 1998 Jun 1;6(3):263-9. https://doi.org/10.1097/00019442-199800630-00009
  9. Fall PA, Ekman R, Granerus AK, Thorell LH, Wålinder J. ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides. Journal of Neural Transmission-Parkinson's Disease and Dementia Section. 1995 Jun 1;10(2-3):129-40. https://doi.org/10.1007/bf02251228
  10. Yoshida K, Higuchi H, Kamata M, Yoshimoto M, Shimizu T, Hishikawa Y. Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1998 Feb 1;22(2):435-44. https://doi.org/10.1016/s0278-5846(98)00015-3
  11. George MS, Lisanby SH, Sackeim HA. Transcranial magnetic stimulation: applications in neuropsychiatry. Archives of General Psychiatry. 1999 Apr 1;56(4):300-11. https://doi.org/10.1001/archpsyc.56.4.300
  12. Cantello R. Applications of transcranial magnetic stimulation in movement disorders. Journal of Clinical Neurophysiology. 2002 Aug 1;19(4):272-93. https://doi.org/10.1097/00004691-200208000-00003
  13. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. Journal of Neurology, Neurosurgery & Psychiatry. 2005 Apr 1;76(4):469-75. https://doi.org/10.1136/jnnp.2004.054635
  14. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW, CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. New England Journal of Medicine. 2000 Sep 28;343(13):898-904. https://doi.org/10.1016/s0002-9394(00)00915-6
  15. Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. Journal of Consulting and Clinical Psychology. 2001 Dec;69(6):942. https://doi.org/10.1037//0022-006x.69.6.942
  16. Feinstein A. The neuropsychiatry of multiple sclerosis. The Canadian Journal of Psychiatry. 2004 Mar;49(3):157-63.